Eloralintide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity.

Mazisotine is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Diabetic Neuropathic Pain.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders ...

It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. Shares of ...

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...